We recently published a list of 10 Biggest Gainers of Last Week. In this article, we are going to take a look at where Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) stands against other biggest ...

Suleiman Sandal, a prominent figure within the Sudanese Revolutionary Front (SRF), announced the proposal on Wednesday following a contentious debate within the Tagadum coalition, a broad alliance ...

If you buy something, we may earn an affiliate commission. If there was a menswear equivalent of the food pyramid, men's sweatshirts would take up a significant portion. They’d occupy the second ...

Teva and Sanofi’s duvakitug achieved remission rates up to 47.8% in trials. The drug’s efficacy surpasses that of rivals like Merck and Roche in placebo-adjusted responses. The TL1A class ...

A significant proportion of subjects with UC who were treated with the therapy achieved clinical remission in the study. Credit: Wasan Tita/Shutterstock. Sanofi and Teva Pharmaceuticals have reported ...

Mr. Mahler typifies a cohort of men — often younger, yes, but also unbothered by the material’s many clichés — that have leaned into leather. There’s Shaboozey, the country-rap warbler ...

Teva stock catapulted Tuesday after its inflammatory bowel disease treatment showed "best-in-class potential" in a Phase 2 study. Researchers Found A Link Between This Childhood Virus And ...

Chesnot / Getty Images Teva Pharmaceuticals and Sanofi on Tuesday reported positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn's disease. The companies plan to ...

Teva Pharmaceuticals’TEVA0.63%increase; green up pointing triangle shares soared and Sanofi’sSAN-0.33%decrease; red down pointing triangle stock moved higher following positive results from ...

As the most discerning, up-to-the-minute voice in all things travel, Condé Nast Traveler is the global citizen’s bible and muse, offering both inspiration and vital intel. We understand that ...

The anti-TL1A antibody allowed significantly more inflammatory bowel disease (IBD) patients to go into remission than those taking placebo treatment. Teva announced it was partnering with Sanofi to ...

On Tuesday, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Sanofi SA’s (NASDAQ:SNY) Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC ...